ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1853 • ACR Convergence 2023

    Each Joint in a 28 Joint Count Is More Likely to Be Affected by Deformity/Limited Motion Than by Swelling in Rheumatoid Arthritis Patients with Long Disease Duration: Deformity/Limited Motion Should Be Included in Joint Counts Performed in Routine Care

    Rahel Hunter1, Nicholas Rodwell2 and Theodore Pincus1, 1Rush University Medical Center, Chicago, IL, 2Liverpool Hospital, Liverpool, Australia

    Background/Purpose: The 28 joint count for rheumatoid arthritis (RA) was designed to recognize 3 abnormalities: swelling, (SWL), tenderness/pain on motion (TEN), and deformity/limited motion (DEF),…
  • Abstract Number: 1915 • ACR Convergence 2023

    Scleritis and Development of Autoimmune Disease: A Case Series

    Tessalyn Morrison1, Moriah Gottman2, Marcia Friedman3 and Daniela Ghetie4, 1University of Vermont, Burlington, VT, 2Oregon Health & Science University, Milwaukie, OR, 3Alpine Immune Sciences, Inc., Beaverton, OR, 4Oregon Health & Science University, Portland, OR

    Background/Purpose: Scleritis involves inflammation of the sclera caused by trauma, infections, or autoimmune conditions. The purpose of our study was to understand the relationship between…
  • Abstract Number: 2103 • ACR Convergence 2023

    Inflammation and Immunomodulatory Therapies Influence the Relationship Between ATP-binding Cassette Transporter A1 (ABCA1)-mediated Cholesterol Efflux and Coronary Atherosclerosis in Rheumatoid Arthritis

    George Karpouzas1, Bianca Papotti2, Sarah Ormseth3, Marcella Palumbo2, Elizabeth Hernandez3, Maria Pia Adorni4, Francesca Zimetti2, Matthew Budoff1 and Nicoletta Ronda2, 1Harbor-UCLA Medical Center, Torrance, CA, 2University of Parma, Department of Food and Drug, Parma, Italy, 3The Lundquist Institute, Torrance, CA, 4Department of Medicine and Surgery, Unit of Neuroscience, University of Parma, Parma, Italy

    Background/Purpose: High-density lipoprotein (HDL) eliminates cholesterol from atherosclerotic lesions, a function known as cholesterol efflux capacity (CEC). ATP-binding-cassette A1 (ABCA1) membrane transporter initiates cholesterol transfer…
  • Abstract Number: 2119 • ACR Convergence 2023

    Serum Alarmin Concentrations and Risk of Incident Major Adverse Cardiovascular Events and Heart Failure in a Multicenter, Prospective Rheumatoid Arthritis Cohort

    Tate Johnson1, Yangyuna Yang1, Punyasha Roul1, Michael Duryee1, Carlos Hunter1, Joshua Baker2, Brian Sauer3, Grant Cannon4, Amy Joseph5, K Wysham6, Aleksander Lenert7, Geoffrey Thiele1, Jill Poole1, Ted R Mikuls8 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3Salt Lake City VA/University of Utah, Salt Lake City, UT, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5Washington University / St. Louis VA, St. Louis, MO, 6VA Puget Sound/University of Washington, Seattle, WA, 7University of Iowa, Iowa City, IA, 8Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Alarmins are endogenous cytokines released following cellular damage and physiologic stress to promote homeostasis through tissue inflammation, remodeling, and fibrosis. Alarmins may facilitate maladaptive…
  • Abstract Number: 2135 • ACR Convergence 2023

    Synovial Fluid High-density Lipoprotein (HDL)-miR-1246 Is Enriched in Patients with Inflammatory Arthritis Compared to Osteoarthritis and Increases Synovial Fibroblast IL-6 Expression

    Olivia Posey1, Qiong Wu1, Anastasiia Phothisane1, Christine Pham2, Deborah Parks2, Antonina Akk3, Danielle Michell1, Kasey Vickers1 and Michelle Ormseth1, 1Vanderbilt University Medical Center, Nashville, TN, 2Washington University, St. Louis, MO, 3Washington University in St. Louis, St. Louis, MO

    Background/Purpose: High-density lipoprotein (HDL), known for its anti-atherogenic reverse cholesterol transport function, also transports miRNAs between cells, altering cellular function. We found that compared to…
  • Abstract Number: 2151 • ACR Convergence 2023

    Effects of Methotrexate on Blood Pressure in Rheumatoid Arthritis: A Randomized Controlled Trial

    Sara Tommasi1, Richard Woodman1, Michael Wiese2, Michael Shanahan1 and Arduino Mangoni1, 1Flinders University, Adelaide, Australia, 2University of South Australia, Adelaide, Australia

    Background/Purpose: Treatment with methotrexate (MTX) has been shown to be associated with lower cardiovascular risk and lower blood pressure (BP) compared with other disease modifying…
  • Abstract Number: 2168 • ACR Convergence 2023

    The Potential of Autologous Patient-derived Circulating Extracellular Vesicles to Improve Drug Delivery in Rheumatoid Arthritis

    Gilad Halpert1, Ori Moskovitch1, Adi Anaki2, Tal Caller1, Omer Gendelman1, Abdulla watad1, Ruty Mehrian-Shai1, Rachella Popovtzer2, Boris Guilbord1, Ori Segal1 and Howard AMITAL1, 1Sheba Medical Center, Ramat Gan, Israel, 2Bar Ilan University, Ramat Gan, Israel

    Background/Purpose: The use of biological treatment in patients with rheumatoid arthritis (RA) can induce non-specific immune suppression, which might result in higher rates of infections.…
  • Abstract Number: 2436 • ACR Convergence 2023

    Characterizing Spatial Organization of Immune Infiltrates in Rheumatoid Arthritis Synovia Using Spatial Transcriptomic Analysis

    Roopa Madhu1, Kartik Bhamidipati1, Anna Helena Jonsson1, Fan Zhang2, Lucy MacDonald3, Youngmi Kim4, Yi Cui4, STARS BWH1, Accelerating Medicines Partnership Program RA SLE Network5, Mariola Kurowska-Stolarska3, Stefano Alvernini6, Ellen Gravallese7, Michael Brenner7, Soumya Raychaudhuri1, Kevin Wei7 and ilya Korsunsky1, 1Brigham and Women's Hospital, Boston, MA, 2University of Colorado, Aurora, CO, 3Research into Inflammatory Arthritis Centre Versus Arthritis (RACE), University of Glasgow, Glasgow, United Kingdom, 4Nanostring, Seattle, WA, 5Cedars-Sinai Medical Center, Los Angeles, CA, 6Division of Rheumatology, Università Cattolica del Sacro Cuore, Rome, Italy, 7Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by immune infiltration of the synovial tissue lining joints. RA is clinically heterogenous, with patients having…
  • Abstract Number: 2533 • ACR Convergence 2023

    Real-world Evidence for Assessing Mortality Disparity Between the Patients with Rheumatoid Arthritis and the General Population in Japan: Results from the IORRA Study

    Naohiro Sugitani1, Eiichi Tanaka2, Eisuke Inoue3, Mai Abe1, Eri Sugano1, Kumiko Saka1, Moeko Ochiai4, Rei Yamaguchi1, Katsunori Ikari5, Ayako Nakajima6, Hisashi Yamanaka7 and Masayoshi Harigai8, 1Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Shinjunku-ku, Japan, 2Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 3Research Administration Center, Showa University, Shinagawa-ku, Japan, 4Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine,, Shinjunku-ku, Japan, 5Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 6Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, 7Sanno Medical Center, Tokyo, Japan, 8Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan

    Background/Purpose: Patients with rheumatoid arthritis (RA) have been reported to have higher mortality rates than the general population. Our previous report showed that the standardized…
  • Abstract Number: PP08 • ACR Convergence 2023

    Finding Gratitude in Adversity: The Impact of Finding the Right Rheumatologist

    Yaideliz Acevedo, Global Healthy Living Foundation, Newark, NJ

    Background/Purpose: I recall sitting in the doctor's office with my one-month-old baby in his stroller, hearing the words "You have rheumatoid arthritis." At 21, I…
  • Abstract Number: 0021 • ACR Convergence 2023

    Shared Genetic Susceptibility Between Rheumatoid Arthritis and Bipolar Disorder: Analyses from Genome-Wide Association Studies

    Jiayi Zheng1, Ruoning Ni2, Nevena Barjaktarovic3 and Yiming Luo4, 1The Wright Center for Graduate Medical Education, Scranton, PA, 2University of Iowa Hospitals and Clinics, Coralville, IA, 3The Wright Center for Community Health, South Abington Township, PA, 4Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, New York, NY

    Background/Purpose: Rheumatoid arthritis (RA) has been associated with bipolar disorder (BD) in epidemiological studies, including a recent Mendelian randomization analysis. This study aims to prioritize…
  • Abstract Number: 0082 • ACR Convergence 2023

    A VAV1-Directed Molecular Glue Degrader, MRT-6160, Reduces Joint Inflammation in a Collagen-Induced Arthritis Autoimmune Disease Model

    Adam Cartwright1, Foram Desai2, Sophia Nguyen2, Alexandra Trouilloud2, Elisa Liardo1, Daric Wible2, Ilaria Lamberto2, Bradley Demarco2, Chris King2, Debora Bonenfant1, Sharon Townson2, Owen Wallace2, Filip Janku2, Laura McAllister1, Alison Paterson2 and Marisa Peluso2, 1Monte Rosa Therapeutics, Basel, Switzerland, 2Monte Rosa Therapeutics, Boston, MA

    Background/Purpose: VAV1 is a member of the VAV family of guanine nucleotide exchange factors (GEFs) and plays a critical role in mediating T- and B-cell…
  • Abstract Number: 0218 • ACR Convergence 2023

    Incidence and Risk Factors for Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients with Systemic Autoimmune Rheumatic Diseases

    Yumeko Kawano1, Xiaosong Wang1, Naomi Patel2, Grace Qian1, Emily Kowalski1, Katarina Bade3, Kathleen Vanni1, Accelerating Medicines Partnership (AMP): RA/SLE1, Zachary Williams2, Claire Cook2, Shruthi Srivatsan2, Zachary Wallace4 and Jeffrey Sparks5, 1Brigham and Women's Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Massachusetts General Hospital, Newton, MA, 5Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: During the height of the COVID-19 pandemic in the United States, tixagevimab/cilgavimab (Evusheld), a combination of monoclonal antibodies directed against the SARS-CoV2 spike protein,…
  • Abstract Number: 0384 • ACR Convergence 2023

    Targeting NET Formation in Early RA Patients; A Spin-off Study from the NORD-STAR

    Bas Dijkshoorn1, Ting Wang2, Gerdur Maria Grondal3, Daisy Vedder4, Anna Rudin5, Dan Nordstrom6, Bjorn Gudbjornsson7, Kristina Lend8, Till Uhlig9, Espen Haavardsholm9, Merete L Hetland10, Marte Schrumpf Heiberg11, Mikkel Østergaard12, Kim Horslev-Petersen13, John Lampa14, Ronald van Vollenhoven15, Christian Lood2 and Michael Nurmohamed16, 1Amsterdam Rheumatology and Immunology Center, Location Reade, Amsterdam, Netherlands, 2University of Washington, Seattle, WA, 3Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, 4Reade, Amsterdam, Netherlands, 5Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 6Helsinki University Hospital, Helsinki, Finland, 7Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, 8Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, 9Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 10Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, 11Diakonhjemmet Hospital, Oslo, Norway, 12Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, 13Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, 14Stockholm County, Hãsselby, Sweden, 15Amsterdam University Medical Centers, Amsterdam, Netherlands, 16Amsterdam University Medical Centers, Kortenhoef, Netherlands

    Background/Purpose: The formation of neutrophil extracellular traps (NETs) with extrusion of nuclear, granular and cytosolic components from a dying neutrophil, has been described extensively in…
  • Abstract Number: 0400 • ACR Convergence 2023

    Thresholds of Presenteeism Measurement Instruments for Unacceptable Work Participation and Future Adverse Work Outcomes in Rheumatoid Arthritis

    Dafne Capelusnik1, Sofia Ramiro2, Elena Nikiphorou3, Walter P. Maksymowych4, Marina Nighat Magrey5, Helena Marzo-Ortega6 and Annelies Boonen7, 1Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3King's College London, London, United Kingdom, 4University of Alberta, Edmonton, AB, Canada, 5Case Western Reserve University, University Hospitals, Cleveland, OH, 6NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 7Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands

    Background/Purpose: Presenteeism is associated with lower work satisfaction and increased risk of future sick leave in rheumatic diseases. It is generally measured on a continuous…
  • « Previous Page
  • 1
  • …
  • 83
  • 84
  • 85
  • 86
  • 87
  • …
  • 219
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology